Replies to post #206071 on Biotech Values

[mcbio]

QURE -

Nothing too surprising given the evolving GT space. I actually think the market may be too harsh today especially since Hem B program has a good chance to be first to market.

Have to wonder at this valuation if basically getting a free shot on goal with Hem B program with decent shot of success and decent upside if it succeeds and not much downside if it fails (EV near zero). Part of me wants to consider a position and then if Hem B fails, take my lumps (hopefully small) and move on. No position right now but on my watchlist.